2. Article

Izteikt 1. pielikuma 2.1.2. apakšpunktu šādā redakcijā: "2.1.2. endogēnie anaboliskie androgēnie steroīdi2: 19-norandrostenediol (estr-4-ene-3,17-diol) 19-norandrostenedione (estr-4-ene-3,17-dione) androstenediol (androst-5-ene-3β,17β-diol) androstenedione (androst-4-ene-3,17-dione) boldenone boldione (androsta-1,4-diene-3,17-dione) dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) nandrolone (19-nortestosterone) prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one) testosterone un to metabolīti un izomēri, tai skaitā: 3β-hydroxy-5α-androstan-17-one 5α-androst-2-ene-17-one 5α-androstane-3α,17α-diol 5α-androstane-3α,17β-diol 5α-androstane-3β,17α-diol 5α-androstane-3β,17β-diol 5β-androstane-3α,17β-diol 7α-hydroxy-DHEA 7β-hydroxy-DHEA 4-androstenediol (androst-4-ene-3β,17β-diol) 5-androstenedione (androst-5-ene-3,17-dione) 7-keto-DHEA 19-norandrosterone 19-noretiocholanolone androst-4-ene-3α,17α-diol androst-4-ene-3α,17β-diol androst-4-ene-3β,17α-diol androst-5-ene-3α,17α-diol androst-5-ene-3α,17β-diol androst-5-ene-3β,17α-diol androsterone epi-dihydrotestosterone epitestosterone etiocholanolone".
Zaudējis spēku - Grozījumi Ministru kabineta 2011. gada 19. oktobra noteikumos Nr. 820 "Dopinga kontroles kārtība", 2. Article · AI Martins